sufentanil citrate · Vertical Pharms · NDA 209128
Dsuvia
Earliest generic entry, as listed
2 Feb 2038
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 11672738.
Listed patents · 21 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11672738 | product | 2 Feb 2038 |
| US 8945592 | product | 29 Jul 2031 |
| US 8202535 | use U-1351 | 22 Oct 2030 |
| US 8865743 | use U-1351 | 22 Oct 2030 |
| US 10896751 | product | 16 Mar 2030 |
| US 11676691 | product | 16 Mar 2030 |
| US 12033733 | product | 16 Mar 2030 |
| US 8574189 | product | 16 Mar 2030 |
| US 10245228 | product, use U-1351 | 5 Jan 2027 |
| US 10342762 | product | 5 Jan 2027 |
| US 10507180 | product, use U-1351 | 5 Jan 2027 |
| US 8226978 | product, use U-1351 | 5 Jan 2027 |
| US 8231900 | product | 5 Jan 2027 |
| US 8252328 | product | 5 Jan 2027 |
| US 8252329 | product | 5 Jan 2027 |
| US 8535714 | product, use U-1351 | 5 Jan 2027 |
| US 8778393 | use U-1351 | 5 Jan 2027 |
| US 8778394 | use U-1351 | 5 Jan 2027 |
| US 8865211 | use U-1351 | 5 Jan 2027 |
| US 9320710 | use U-1351 | 5 Jan 2027 |
| US 9744129 | product | 5 Jan 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 209128 · 001 · RLD · discontinued | tablet, sublingual | EQ 0.03MG BASE | 2 Feb 2038 |